JUNE 4, 2025
Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces its participation to the BIO International Convention, which will
MAY 30, 2025
Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its
MAY 15, 2025
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis announced its active participation at the 32nd European Congress on Obesity (ECO
APRIL 25, 2025
Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended
APRIL 22, 2025
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with
APRIL 9, 2025
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in
MARCH 28, 2025
Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA,
MARCH 26, 2025
Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by
MARCH 24, 2025
Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report
MARCH 17, 2025
Biophytis revolutionizes sarcopenia Biophytis is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia,